New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg and the team of Canadian experts, including our NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
We congratulate Dr. Kerri Schellenberg and the team of Canadian experts, including our NMD4C Steering Committee members and Investigators, on publishing the first Canadian best practice recommendations for the clinical care of spinal bulbar muscular atrophy (SBMA) in the Canadian Medical Association Journal (CMAJ).
These guidelines provide actionable guidance for multidisciplinary care teams to manage motor and non-motor symptoms, support early diagnosis, and ensure timely referrals to specialized care.
The recommendations were developed by leading Canadian clinicians and researchers, including:
- NMD4C Steering Committe Members: Drs. Lawrence Korngut, Gerald Pfeffer, and Jodi Warman Chardon.
- NMD4C Investigators: Drs. Kerri Schellenberg (Lead), Colleen O’Connell, Christen Shoesmith, Alexandra King, and Malcolm King.
- Additional contributing experts: Drs. Gudrun Caspar-Bell, Colin Ellis, Wendy Johnston, Brendan Kushneriuk, Andrea Lavoie, Reid McGonigle, Julia Newton, Oksana Suchowersky, and Shane Wunder.
These guidelines aim to optimize outcomes and support quality of life for individuals living with SBMA. We encourage you to share this important publication with your networks.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.